Skip to main content
OpenTrials
Completed

NCT Number: NCT05003167

Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS

A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength. All participants complete a respiratory strength training program using an Expiratory Muscle Strength Training (EMST 150) device from the comfort of their homes for 6 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Purdue University

West Lafayette, Indiana, 47906, United States

About this study

The investigators are looking for people with early stage ALS to participate in a completely tele-health (no in-person visits required) treatment study examining the effects of an Expiratory Muscle Strength Training device (EMST-150) on communication, cough, and respiratory strength. Participants will be required to attend 2 virtual baseline assessment sessions followed by 12 additional virtual training sessions (2 per week for 6 weeks). Participants should plan to be actively enrolled in the study for ~10 weeks (3 weeks of baseline monitoring followed by 6 weeks of training). Participants will also be required to fill out a series of questionnaires assessing the EMST's effectiveness via tele-health.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of ALS
  • Within the early stages of disease progression (i.e., able to talk, breathe, and eat independently)
  • Speaker of English
  • Have a family member/caregiver willing to assist as needed
  • Have access to an electronic device and internet for tele-health

Exclusion criteria

  • A history of neurological disease (besides ALS)
  • A history of asthma or respiratory problems (e.g., COPD, emphysema)
  • A history of head, neck, or chest surgery (except mastectomy)
  • A history of smoking within the last 5 years
  • Reliance on mechanical ventilation (including CPAP)

Treatment and study plan

Expiratory Muscle Strength Training (EMST-150)

Device

All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).

Primary outcomes

  1. Change From Baseline to Post-treatment for Maximum Expiratory Pressure

    Time frame: Baseline 2 (week 2), Pre-Training (week 3), and Post-Training (week 10)

    Change in expiratory muscle strength throughout the study duration measured by the participant blowing into a pressure meter

Secondary outcomes

  1. Peak Expiratory Flow Rate

    Time frame: Baseline 2 (week 2), Pre-training (week 3), Post-Training (week 10)

    Change in cough strength (as measured by peak expiratory flow rate) throughout the study duration, measured using a flow meter that the participant coughs into - single coughs. Data from baseline 2 and pre-training were averaged for the pre--training value.

  2. Change From Baseline to Post-Treatment in Utterance Length

    Time frame: Baseline 1 (week 1) and Post-Training (week 10)

    Change in utterance length (# of syllables produced on one breath) throughout the study duration. Participant read the Rainbow Passage and data were collected from this task.

  3. Change From Baseline to Post-Treatment in Number of Pauses

    Time frame: Baseline 1 (week 1) and Post-Training (week 10)

    Change in the total number of pauses that included breathing (breath pauses). Participant read the Rainbow Passage and data were collected from this task.

  4. Change From Baseline to Post-Treatment in Syntactic Location of Pauses

    Time frame: Baseline 1 (week 1) and Post-Training (week 10)

    Change in the location of pauses while breathing produced while reading. We determined where participants took breaths while reading the Rainbow Passage and categorized them according to syntax. Categories included at a major boundary (at the end of an independent clause marked by a period) and at a boundary that is not related to syntax (not a major or minor syntactical location). The number of pauses at each category of boundaries were converted to a percent of the total breaths taken while reading the passage.

  5. Telehealth Satisfaction

    Time frame: Post-Training (week 10)

    Participants rated 15 statements with a 5-point Likert scale ranging from strongly disagree (1) to strongly agree (5). Example statements include: I can easily talk to my health-care provider, I can hear my health-care provider clearly, I can see my health-care provider as if we met in person, I think the care provided via telemedicine is consistent, and I receive adequate attention, telemedicine provides for my health care need, and overall, I am satisfied with the quality of service being provided via telemedicine. Total scores range from 0-75 and individual statement scores ranged from 1-5, with higher scores indicating higher satisfaction with the telepractice modality.

  6. Change From Pre-Training to Post-Training in Communication Participation Item Bank

    Time frame: Pre-Training (week 3) and Post-Training (week 10)

    Participants were instructed to use a 4-point Likert scale (3: not at all; 2: a little; 1: quite a bit; 0: very much) to rate if/how their ALS impacts ten hypothetical communicative situations. Participants total scores were then added together, ranging from 0-30, and converted to a T-score ranging from 24.2-71.0. High scores are more favorable, indicating that the participant feels that ALS impacts their communicative participation less than those with lower scores.

  7. Change From Baseline to Post-Treatment in ALS Quality of Life Scale

    Time frame: Baseline 1 (week 1) and Post-Training (week 10)

    The ALS Quality of Life Scale-Revised (ALSQOL-R) (Simmons, 2015) was used to measure how ALS impacts their quality of life in six domains: negative emotion, interaction with people and the environment, intimacy, religiosity, physical symptoms, and bulbar function. Participants rate whether they strongly disagree (0) or strongly agree (10) with 46 statements. Each domain score is given an average value between 0 (worse) and 10 (best). Total scores on the ALSQOL-R range from 0-460, but an average score ranging from 0-10 is computed by dividing the total score by the total number of items completed by the participant (usually 46). Higher scores reflect a higher quality of life. A survey assessing how each participant feels ALS impacts quality of life, and how that changes throughout the study duration. Total scores range from 0-460, with higher scores indicating greater contributions of ALS to quality of life.

  8. ALS Function Rating Scale Revised

    Time frame: Baseline 1 (week 1) and Post-Training (week 10)

    A survey that quantifies change in disease progression throughout the study duration. Participants rate how 12 physical functions are impacted by their ALS. For each function, participants are provided with a 4-point Likert scale to rate whether they still have complete control of that function (4) or no ability to perform that function (0). Total scores range from 0 to 48, with lower scores indicating more severe symptoms and higher scores and less severe symptoms.

  9. Psychosocial Impact of Assistive Devices Scale

    Time frame: Post-treatment (week 10)

    A survey assessing how the training device/modality impacts patient's psychosocial functions. The PIADS includes 12 items for competence, 6 for adaptability, and 8 for self-esteem. Participants use a 7-point Likert scale to rate the impact of a device on each item: a maximum negative impact (-3), somewhat negative impact (-2 or -1), zero impact (0), somewhat positive impact (1 or 2), maximum positive impact (3). Total scores range from -78 (maximum negative impact) to 78 (maximum positive impact).

  10. Tele-health Session Attendance

    Time frame: Measured at the end of training across the entire training period

    % of training sessions scheduled and attended by participants throughout the study duration

  11. Adherence to Training Protocol

    Time frame: Measured each week of training across the entire training duration

    Number of of training exhalations completed (25 exhalations into the device, 5 days per week) by participants throughout the study duration

Sponsors and collaborators

Lead sponsor

Purdue University

Other

Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 12, 2021
Registry last updated
Jun 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.